New leader of business development at Compugen

, , , , ,

Compugen Ltd. has appointed Oliver Froescheis, Ph.D., as senior VP, corporate and business development. In his role, Dr. Froescheis will oversee the company’s business development strategy and execution, reporting to Anat Cohen-Dayag, Ph.D., Compugen’s president and CEO.

“We are delighted to have an executive with Oliver’s proven track record in the pharmaceutical industry join Compugen’s management team,” Dr. Cohen-Dayag says. “Oliver’s breadth of healthcare experience and broad expertise in the development and licensing of pharmaceuticals across various therapeutic areas including immuno-oncology makes him a strong addition to our company as we work to expand our innovative immuno-oncology pipeline and pursue additional collaboration opportunities.”

Dr. Froescheis joins Compugen from Roche’s Partnering organization where he most recently served as director of business development and licensing R&D out-licensing. He holds a diploma in chemistry and a Ph.D. in analytical chemistry, both from the University of Ulm, Germany.

“Compugen has made tremendous progress in recent years in advancing first-in-class immuno-oncology drug candidates to the clinic, and recently presenting initial promising clinical data for its lead program, COM701,” Dr. Froescheis says. “In addition, Compugen has an impressive track record of collaborations with three big pharma players having successfully leveraged its innovative immuno-oncology portfolio generated from its unique computational capabilities. This innovative portfolio and underlying computational capabilities provide opportunities for future business collaborations. I am excited to join Compugen’s management team to support this effort and be a part of Compugen’s future growth.”

Compugen is a clinical-stage cancer immunotherapy company and a leader in predictive target discovery.